Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emergency Use of Tigecycline for Resistant Infections
NCT00205816Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2004
- Primary completion
- Nov 2005
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of tigecycline in bacterial infection, sponsored by Pfizer. Primary endpoint: Clinical Response. Started Jan 2004; status: completed.
02
Drugs
tigecycline
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT00205816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00205816.